View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 10, 2021updated 12 Jul 2022 11:22am

Melior Pharmaceuticals to initiate trial of Covid-19 drug

Melior Pharmaceuticals is all set to initiate a planned Phase II study of its novel, first-in-class lyn kinase activator, tolimidone, for Covid-19 treatment.  

Melior Pharmaceuticals is set to initiate a planned Phase II study of its novel, first-in-class lyn kinase activator, tolimidone, for Covid-19 treatment.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Tolimidone is a repositioned drug that was shown to be safe and well-tolerated in prior clinical studies.

The latest development comes after the company received clearance of its Investigational New Drug (IND) application for tolimidone’s clinical development.

The trial will enrol 236 participants recently diagnosed with Covid-19. The patients will have early symptoms but will not have been hospitalised. They will take the drug as an orally administered pill once daily.

According to pre-clinical studies in animal models of Covid-19, tolimidone is a therapeutic that can potentially alleviate the incidence and severity of pulmonary symptoms in Covid-19 and other diseases linked to pulmonary complications that arise due to cytokine storm, including sepsis.

Melior Pharmaceuticals CEO Andrew Reaume said: “We are very proud of the fact that in less than a year since Covid-19 was declared a global pandemic, we developed and tested hypotheses, discovered a therapeutic candidate, and have progressed today with an active IND for what is a truly innovative therapy.

“Moreover, tolimidone holds promise as a novel form of therapy for a number of other pulmonary related diseases beyond Covid-19.”

Tolimidone can activate an enzyme in charge of maintaining the pulmonary barrier and averting the leakage of fluid into the lungs, as seen in Covid-19 patients cytokine storm, the runaway immune response.

Last September, Melior received a grant from the Commonwealth of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program, designed to aid in the quick advancement of promising Covid-19 treatments.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena